EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment

Fathima Paleel, Mengqi Qin, Aristides D Tagalakis, Cynthia Yu-Wai-Man, Dimitrios A Lamprou iD

Drug Delivery and Translational Research · 2025

DOI: 10.1007/s13346-024-01589-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Fathima Paleel und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Queen's University Belfast, BT9 7BL, Belfast, UK. Hauptthemen laut MEDLINE: Timolol, Printing, Three-Dimensional, Delayed-Action Preparations, Glaucoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Timolol maleate (TML) is a beta-blocker drug that is commonly used to lower the intraocular pressure in glaucoma. This study focused on using a 3D printing (3DP) method for the manufacturing of an ocular, implantable, sustained-release drug delivery system (DDS). Polycaprolactone (PCL), and PCL with 5 or 10% TML implants were manufactured using a one-step 3DP process. Their physicochemical characteristics were analysed using light microscopy, scanning electronic microscopy (SEM), differential scanning calorimetry (DSC) / thermal gravimetric analysis (TGA), and Fourier-transform infrared spectroscopy (FTIR). The in vitro drug release was evaluated by UV-spectrophotometry. Finally, the effect of the implants on cell viability in human trabecular meshwork cells was assessed. All the implants showed a smooth surface. Thermal analysis demonstrated that the implants remained thermally stable at the temperatures used for the printing, and FTIR studies showed that there were no significant interactions between PCL and TML. Both concentrations (5 & 10%) of TML achieved sustained release from the implants over the 8-week study period. All implants were non-cytotoxic to human trabecular cells. This study shows proof of concept that 3DP can be used to print biocompatible and personalised ocular implantable sustained-release DDSs for the treatment of glaucoma. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TimololPrinting, Three-DimensionalDelayed-Action PreparationsGlaucomaPolyestersDrug LiberationCell SurvivalDrug ImplantsHumansTrabecular MeshworkCells, Cultured

Stichwörter der Autor:innen

3D printingDrug-eluting implantsGlaucomaSustained-releaseTimolol

Substanzen

TimololDelayed-Action PreparationsPolyesterspolycaprolactoneDrug Implants

Autor:innen und Institutionen

  • School of Pharmacy, Queen's University Belfast, BT9 7BL, Belfast, UK.
  • Faculty of Life Sciences & Medicine, King's College London, SE1 7EH, London, UK.
  • Department of Biology, Edge Hill University, L39 4QP, Ormskirk, UK.
  • Faculty of Life Sciences & Medicine, King's College London, SE1 7EH, London, UK. cynthia.yu-wai-man@kcl.ac.uk.
  • School of Pharmacy, Queen's University Belfast, BT9 7BL, Belfast, UK. d.lamprou@qub.ac.uk.

ORCID-Profile: Dimitrios A Lamprou

Förderung

  • Medical Research Council

Zitieren

APA

Paleel, F., Qin, M., Tagalakis, A. D., Yu-Wai-Man, C., & Lamprou, D. A. (2025). Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01589-8

Vancouver

Paleel F, Qin M, Tagalakis AD, Yu-Wai-Man C, Lamprou DA. Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01589-8

BibTeX
@article{Paleel2025,
  author = {Paleel, Fathima and Qin, Mengqi and Tagalakis, Aristides D and Yu-Wai-Man, Cynthia and Lamprou, Dimitrios A},
  title = {Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment},
  journal = {Drug Delivery and Translational Research},
  year = {2025},
  doi = {10.1007/s13346-024-01589-8}
}
Kostenlos starten →